- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05636215
A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Peng An
- Phone Number: +86 18310080353
- Email: alisa.an@innoventbio.com
Study Locations
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- Scientia Clinical Research Ltd
-
Contact:
- Charlotte Lemech
- Phone Number: 61293825807
- Email: Charlotte.lemech@scientiaclinicalresearch.com.au
-
-
Queensland
-
Sunshine Coast, Queensland, Australia, 4575
- Sunshine Coast University Private Hospital
-
Contact:
- Michelle Morris
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Monash Health
-
Contact:
- Daphne Day
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects, ≥ 18 years
Phase 1a : Has a pathologically documented advanced/unresectable or metastatic solid tumor with HER2 alterations (IHC 1+, IHC 2+, IHC 3+ and/or ISH+ and/or NGS confirmed mutant or amplification).
Phase 1b/2: Selected solid tumors enrolled Subjects with advanced GC/BC/BTC/CRC/Gyn with her2 expression (IHC 1+, IHC 2+, IHC 3+ and/or ISH+).
- Adequate bone marrow and organ function
- Subjects, both male and female, who are either not of childbearing potential or who agree to use at least one highly effective method of contraception during the study (begin from screening or within 2 weeks prior to the first dose, whichever comes first, and continue until 6 months after the last dose of study drug); Subjects, both male and female, who are either not of childbearing potential or who agree to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug
- Subjects with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol;
- Have LVEF ≥ 50% by echocardiography (ECHO) within 28 days before study drug administration.
Exclusion Criteria:
- Received previous anti-tumor therapy within 4 weeks or 5 half-lives of the anti-tumor regimens before the first administration of study drug, whichever is shorter;
- Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also do not have impact on tumor assessment throughout the study;
- Potent cytochrome P450 3A4 (CYP3A4) inhibitors within 2 weeks or 5 half-lives (whichever is longer) before first administration of the study drug.
- Has adverse reactions resulting from previous antitumor therapies, which have not resolved to Grade 0 or 1 toxicity according to NCI-CTCAE v5.0 (except for alopecia, fatigue, pigmentation and other conditions with no safety risk according to investigators' opinion) or baseline prior to first administration of the study drug;
- Known symptomatic central nervous system (CNS) metastases.
- History of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases or who are suspected to have these diseases by imaging at screening period;
Uncontrolled diseases including:
- Uncontrolled infection requiring systematic antibiotics, antivirals or antifungals within 2 weeks prior to first administration of the study drug;
- Known human immunodeficiency virus (HIV) infection, or HIV positive (HIV 1/2 Ab positive);
- HBsAg positive and/or HBcAb positive with HBV DNA titer ≥ 104 copies/mL or ≥ 2000 IU/mL or higher than lower limit of detection or HCV Ab positive with HCV RNA>103 copies/mL;
- Active infection with COVID-19;
- Active tuberculosis infection, or still on anti-tuberculosis therapy or received anti-tuberculosis therapy within 1 year prior to first administration of the study drug;
- Active syphilis infection or latent syphilis requiring treatment;
- Symptomatic congestive heart failure Grade II-IV, symptomatic or uncontrolled arrhythmias, QTc interval > 480 ms or personal or family history of congenital long/short QT syndrome;
- SBP ≥ 160mmHg or DBP ≥ 100mmHg;
- History of any arterial thromboembolic event within 6 months prior to the first administration of study drug, including myocardial infarction, unstable angina pectoris, cerebrovascular stroke or transient ischemic attack, etc.;
- Risk of intestinal obstruction or perforation (including but not limited to: acute diverticulitis, abdominal abscess, etc.) or a history of inflammatory bowel disease, Crohn's disease, ulcerative colitis, or chronic diarrhea;
Do not have adequate treatment washout period before study drug administration, defined as:
- Major surgery; ≥ 4 weeks.
- Radiation therapy;≥ 4 weeks (if palliative stereotactic radiation therapy, ≥ 2 weeks).
- Autologous transplantation;≥ 3 months.
- Hormonal therapy;≥ 2 weeks.
- Chemotherapy (including antibody drug therapy or other antitumor therapy); ≥ 3 weeks.
- Immunotherapy; ≥ 4 weeks.
- Cytochrome P450 (CYP) 3A4 strong inhibitor;≥ 3 elimination half-lives of the inhibitor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IBI354
Single arm
|
Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugate for injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of serious adverse events (SAEs), treatment-emergent AEs (TEAEs).
Time Frame: Up to 30 days after the last administration
|
An SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is an important medical event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed before.
A TEAE will be defined as any new AE that begins, or any pre-existing condition that worsens in severity, after at least 1 dose of study treatment has been administered.
|
Up to 30 days after the last administration
|
Number of dose-limiting toxicity (DLT)
Time Frame: 21 days during the first cycle in Phase Ia
|
Incidence of dose-limiting toxicity (DLT) events.
|
21 days during the first cycle in Phase Ia
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to 2 years
|
ORR is defined as the proportion of participants with a complete response (CR) or partial response (PR).
|
Up to 2 years
|
duration of response (DoR)
Time Frame: Up to 2 years
|
DoR is defined as the time from the date of first documented tumor response (CR/PR) until PD/death.
|
Up to 2 years
|
progression-free survival (PFS)
Time Frame: Up to 2 years
|
PFS is defined as the time from the date of first dose of study drug to the date of the first documented progression or death due to any cause, whichever occurs first.
|
Up to 2 years
|
Overall survival (OS)
Time Frame: Up to 2 years
|
OS is defined as the time from the date of first dose of study drug until the date of death from any cause.
|
Up to 2 years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIBI354A101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Unresectable or Metastatic Solid Tumors
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States
-
Txinno Bioscience Inc.RecruitingLocally Advanced (Unresectable) or Metastatic Solid TumorsKorea, Republic of
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyRecruitingMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, Canada, Spain
-
Hangzhou Sumgen Biotech Co., Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsChina
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, China, Spain, Japan, United Kingdom
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, Canada
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Shanghai Xianxiang Medical Technology Co., Ltd.; Simcere ZaimingRecruitingLocally Advanced Unresectable or Metastatic Solid TumorUnited States, China
-
Astellas Pharma IncCompletedLocally Advanced (Unresectable) or Metastatic Solid Tumor MalignanciesJapan